Cargando…
Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin
AIMS/INTRODUCTION: To identify the effect of combination therapy with a dipeptidyl peptidase‐4 inhibitor and a sodium–glucose cotransporter 2 inhibitor compared with switching from a dipeptidyl peptidase‐4 inhibitor to a sodium–glucose cotransporter 2 inhibitor on improving the glucose variability i...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354506/ https://www.ncbi.nlm.nih.gov/pubmed/33325645 http://dx.doi.org/10.1111/jdi.13479 |
_version_ | 1783736607327649792 |
---|---|
author | Miya, Aika Nakamura, Akinobu Cho, Kyu Yong Kawata, Shinichiro Nomoto, Hiroshi Nagai, So Sugawara, Hajime Taneda, Shinji Tsuchida, Kazuhisa Omori, Kazuno Yokoyama, Hiroki Takeuchi, Jun Aoki, Shin Kurihara, Yoshio Atsumi, Tatsuya Miyoshi, Hideaki |
author_facet | Miya, Aika Nakamura, Akinobu Cho, Kyu Yong Kawata, Shinichiro Nomoto, Hiroshi Nagai, So Sugawara, Hajime Taneda, Shinji Tsuchida, Kazuhisa Omori, Kazuno Yokoyama, Hiroki Takeuchi, Jun Aoki, Shin Kurihara, Yoshio Atsumi, Tatsuya Miyoshi, Hideaki |
author_sort | Miya, Aika |
collection | PubMed |
description | AIMS/INTRODUCTION: To identify the effect of combination therapy with a dipeptidyl peptidase‐4 inhibitor and a sodium–glucose cotransporter 2 inhibitor compared with switching from a dipeptidyl peptidase‐4 inhibitor to a sodium–glucose cotransporter 2 inhibitor on improving the glucose variability in patients with or without impaired endogenous insulin secretion. MATERIALS AND METHODS: A secondary analysis regarding the relationship between endogenous insulin secretion and the change in mean amplitude of glycemic excursions (ΔMAGE) was carried out in a multicenter, prospective, randomized, parallel‐group comparison trial that enrolled patients with type 2 diabetes who had been taking teneligliptin and were treated by switching to canagliflozin (SWITCH) or adding canagliflozin (COMB). Participants were categorized into the following four subgroups: SWITCH or COMB and high or low fasting C‐peptide (CPR) divided at baseline by the median. RESULTS: ΔMAGE in the COMB group was greatly improved independent of a high or low CPR (−29.2 ± 28.3 vs −20.0 ± 24.6, respectively; P = 0.60). However, ΔMAGE was not ameliorated in the low CPR SWITCH group, and the ΔMAGE was significantly smaller than that in the high CPR COMB group (P < 0.01). CONCLUSIONS: COMB would be a better protocol rather than switching teneligliptin to canagliflozin to improve daily glucose variability in patients with impaired endogenous insulin secretion. |
format | Online Article Text |
id | pubmed-8354506 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83545062021-08-15 Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin Miya, Aika Nakamura, Akinobu Cho, Kyu Yong Kawata, Shinichiro Nomoto, Hiroshi Nagai, So Sugawara, Hajime Taneda, Shinji Tsuchida, Kazuhisa Omori, Kazuno Yokoyama, Hiroki Takeuchi, Jun Aoki, Shin Kurihara, Yoshio Atsumi, Tatsuya Miyoshi, Hideaki J Diabetes Investig Articles AIMS/INTRODUCTION: To identify the effect of combination therapy with a dipeptidyl peptidase‐4 inhibitor and a sodium–glucose cotransporter 2 inhibitor compared with switching from a dipeptidyl peptidase‐4 inhibitor to a sodium–glucose cotransporter 2 inhibitor on improving the glucose variability in patients with or without impaired endogenous insulin secretion. MATERIALS AND METHODS: A secondary analysis regarding the relationship between endogenous insulin secretion and the change in mean amplitude of glycemic excursions (ΔMAGE) was carried out in a multicenter, prospective, randomized, parallel‐group comparison trial that enrolled patients with type 2 diabetes who had been taking teneligliptin and were treated by switching to canagliflozin (SWITCH) or adding canagliflozin (COMB). Participants were categorized into the following four subgroups: SWITCH or COMB and high or low fasting C‐peptide (CPR) divided at baseline by the median. RESULTS: ΔMAGE in the COMB group was greatly improved independent of a high or low CPR (−29.2 ± 28.3 vs −20.0 ± 24.6, respectively; P = 0.60). However, ΔMAGE was not ameliorated in the low CPR SWITCH group, and the ΔMAGE was significantly smaller than that in the high CPR COMB group (P < 0.01). CONCLUSIONS: COMB would be a better protocol rather than switching teneligliptin to canagliflozin to improve daily glucose variability in patients with impaired endogenous insulin secretion. John Wiley and Sons Inc. 2021-01-21 2021-08 /pmc/articles/PMC8354506/ /pubmed/33325645 http://dx.doi.org/10.1111/jdi.13479 Text en © 2020 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Articles Miya, Aika Nakamura, Akinobu Cho, Kyu Yong Kawata, Shinichiro Nomoto, Hiroshi Nagai, So Sugawara, Hajime Taneda, Shinji Tsuchida, Kazuhisa Omori, Kazuno Yokoyama, Hiroki Takeuchi, Jun Aoki, Shin Kurihara, Yoshio Atsumi, Tatsuya Miyoshi, Hideaki Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin |
title | Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin |
title_full | Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin |
title_fullStr | Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin |
title_full_unstemmed | Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin |
title_short | Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin |
title_sort | impact of endogenous insulin secretion on the improvement of glucose variability in japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354506/ https://www.ncbi.nlm.nih.gov/pubmed/33325645 http://dx.doi.org/10.1111/jdi.13479 |
work_keys_str_mv | AT miyaaika impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin AT nakamuraakinobu impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin AT chokyuyong impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin AT kawatashinichiro impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin AT nomotohiroshi impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin AT nagaiso impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin AT sugawarahajime impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin AT tanedashinji impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin AT tsuchidakazuhisa impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin AT omorikazuno impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin AT yokoyamahiroki impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin AT takeuchijun impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin AT aokishin impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin AT kuriharayoshio impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin AT atsumitatsuya impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin AT miyoshihideaki impactofendogenousinsulinsecretionontheimprovementofglucosevariabilityinjapanesepatientswithtype2diabetestreatedwithcanagliflozinplusteneligliptin |